SCHEMBL3014955

SCHEMBL3014955

O=S(=O)(c1cccc(Cl)c1)N1CCN(c2nc(-c3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.60
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MAPT P10636 3/20 0.48
USP2 O75604 1/20 0.48
RECQL P46063 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GBA1 P04062 2/20 0.47
LMNA P02545 4/20 0.46
NPSR1 Q6W5P4 1/20 0.46
POLB P06746 1/20 0.46
HSD11B1 P28845 1/20 0.46
KDM1A O60341 1/20 0.46
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
RAB9A P51151 1/20 0.44
CHRM4 P08173 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011492 0.92 AR (0.56) ARMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3017855 0.92 AR (0.56) ARMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3014225 0.91 AR (0.63) ARMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3006931 0.90 AR (0.64) ARMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2997717 0.89 AR (0.60) ARMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3010933 0.89 AR (0.53) ARMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3008900 0.89 AR (0.53) ARMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3017609 0.88 SMN1; SMN2 (0.62) MEN1KMT2AALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3000502 0.88 AR (0.58) ARMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3019049 0.87 MAPT (0.48) ARMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.